Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison
Andrew Menzies‐Gow, Jason Steenkamp, Sumeet Singh, et al.
Journal of Medical Economics (2022) Vol. 25, Iss. 1, pp. 679-690
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis
Tanawin Nopsopon, Grace Lassiter, Ming‐Li Chen, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 151, Iss. 3, pp. 747-755
Open Access | Times Cited: 42
Methods for Indirect Treatment Comparison: Results from a Systematic Literature Review
Bérengère Macabeo, Arthur Quenéchdu, Samuel Aballéa, et al.
Journal of Market Access & Health Policy (2024) Vol. 12, Iss. 2, pp. 58-80
Open Access | Times Cited: 12
Hydrolyzable Tannins in the Management of Th1, Th2 and Th17 Inflammatory-Related Diseases
Stefano Piazza, Marco Fumagalli, Giulia Martinelli, et al.
Molecules (2022) Vol. 27, Iss. 21, pp. 7593-7593
Open Access | Times Cited: 27
Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma
Momoko Kurihara, Hiroki Kabata, Misato Irie, et al.
Allergology International (2022) Vol. 72, Iss. 1, pp. 24-30
Open Access | Times Cited: 25
Tezepelumab in patients with allergic and eosinophilic asthma
Marco Caminati, Roland Buhl, Jonathan Corren, et al.
Allergy (2023) Vol. 79, Iss. 5, pp. 1134-1145
Open Access | Times Cited: 15
Comparative Effectiveness of Dupilumab and Omalizumab on Asthma Exacerbations and Systemic Corticosteroid Prescriptions: Real-World US ADVANTAGE Study
Eugene R. Bleecker, Michael S. Blaiss, Juby A. Jacob‐Nara, et al.
Journal of Allergy and Clinical Immunology (2024) Vol. 154, Iss. 6, pp. 1500-1510
Open Access | Times Cited: 4
Effectiveness of biologics for patients with severe asthma: study protocol for an umbrella review of systematic reviews and meta-analyses
Qionghua Xiao, Xue Bai, Yuanming Huang, et al.
BMJ Open (2025) Vol. 15, Iss. 4, pp. e096874-e096874
Open Access
A comparison of the effectiveness of biologic therapies for asthma
Tyler Pitre, Tanvir Jassal, Albi Angjeli, et al.
Annals of Allergy Asthma & Immunology (2022) Vol. 130, Iss. 5, pp. 595-606
Open Access | Times Cited: 17
Tezepelumab: An Anti-Thymic Stromal Lymphopoietin Monoclonal Antibody for the Treatment of Asthma
Masaharu Shinkai, Tadataka Yabuta
Immunotherapy (2023) Vol. 15, Iss. 17, pp. 1435-1447
Open Access | Times Cited: 10
Comparative efficacy of biologics for patients with inadequately controlled asthma: A network meta-analysis
Hayeon Kim, Myeong Gyu Kim, Sung‐Ryeol Kim, et al.
World Allergy Organization Journal (2024) Vol. 17, Iss. 7, pp. 100934-100934
Open Access | Times Cited: 3
Head‐To‐Head Comparison of Biologic Efficacy in Asthma: What Have We Learned?
Brian J. Lipworth, Robert Greig, Rory Chan, et al.
Allergy (2025)
Open Access
The Acceptance of Indirect Treatment Comparison Methods in Oncology by Health Technology Assessment Agencies in England, France, Germany, Italy, and Spain
Bérengère Macabeo, Théophile Rotrou, A. Millier, et al.
PharmacoEconomics - Open (2023) Vol. 8, Iss. 1, pp. 5-18
Open Access | Times Cited: 7
Effects of Tezepelumab on Quality of Life of Patients with Moderate-to-Severe, Uncontrolled Asthma: Systematic Review and Meta-Analysis
Gabriel Cavalcante Lima Chagas, Débora Pinheiro Xavier, Lorena Gomes, et al.
Current Allergy and Asthma Reports (2023) Vol. 23, Iss. 6, pp. 287-298
Closed Access | Times Cited: 6
Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study
Andrew Menzies‐Gow, Christopher S. Ambrose, Gene Colice, et al.
Advances in Therapy (2023) Vol. 40, Iss. 11, pp. 4957-4971
Open Access | Times Cited: 6
Novel Immunopharmacological Drugs for the Treatment of Allergic Diseases
Ekaterini Tiligada, Daria Gafarov, Maria Zaimi, et al.
The Annual Review of Pharmacology and Toxicology (2023) Vol. 64, Iss. 1, pp. 481-506
Closed Access | Times Cited: 6
An overview of the preclinical discovery and development of tezepelumab for the treatment of asthma
Maria Gabriella Matera, Josuel Ora, Paola Rogliani, et al.
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 9, pp. 951-963
Closed Access | Times Cited: 5
Increasing transparency in indirect treatment comparisons: is selecting effect modifiers the missing part of the puzzle? A review of methodological approaches and critical considerations
Andreas Freitag, Laura Gurskyte, Grammati Sarri
Journal of Comparative Effectiveness Research (2023) Vol. 12, Iss. 10
Open Access | Times Cited: 5
Cost-effectiveness of tezepelumab in Canada for severe asthma
Mara Habash, Hannah Guiang, Irvin Mayers, et al.
Journal of Medical Economics (2023) Vol. 26, Iss. 1, pp. 902-914
Open Access | Times Cited: 4
Monoclonal antibodies targeting small airways: a new perspective for biological therapies in severe asthma
Carlo Lombardi, Marcello Cottini, Alvise Berti, et al.
Asthma Research and Practice (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 7
The Impact of Tezepelumab in Uncontrolled Severe Asthma: A Systematic Review of Randomized Controlled Trials
Pooja Roy, ZAHIN ISLAM RAFA, Sharar Naiarin Haque, et al.
Cureus (2022)
Open Access | Times Cited: 7
Biologics in T2 Severe Asthma: Unveiling Different Effectiveness by Real-World Indirect Comparison
Elisa Riccardi, Giuseppe Guida, Sonia Garino, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 16, pp. 4750-4750
Open Access | Times Cited: 1
Biologics in Asthma
Gabriel Lavoie, Ian Pavord
Immunology and Allergy Clinics of North America (2024) Vol. 44, Iss. 4, pp. 709-723
Closed Access | Times Cited: 1
Direct comparative study of the effectiveness of mepolizumab and dupilumab in patients with severe non-allergic eosinophilic asthma
В. В. Наумова, Е. К. Beltyukov, О. П. Ковтун, et al.
Meditsinskiy sovet = Medical Council (2023), Iss. 20, pp. 18-27
Open Access | Times Cited: 3
A comparison of the effectiveness of biologic therapies for asthma: a systematic review and network meta-analysis
Tyler Pitre, Tanvir Jassal, Albi Angjeli, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 5
Development of a novel humanized anti-TSLP monoclonal antibody, QX008N, and exploration of combination therapy of anti-TSLP antibody and anti-IL-4R antibody
Xiaomu Wang, Yong Kong, Tianquan Qiu, et al.
International Immunopharmacology (2024) Vol. 142, pp. 113102-113102
Closed Access
Page 1 - Next Page

Scroll to top